Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
TWST vs. NTRA: Which Genomics Play Is a Better Buy?
11:53am, Friday, 25'th Jul 2025
Cathie Wood's Ark funds have been really heating up in recent months. Perhaps her most intriguing and underrated fund is the Ark Genomics Revolution ETF (ARKG), which is packed full of extraordinary b
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published fin
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latit
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
04:05pm, Tuesday, 01'st Jul 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical
Nearly 16 % of Druckenmiller's Money Now Rides on This Stock
08:26am, Thursday, 05'th Jun 2025
A high-growth gem is the largest holding in Stanley Druckenmiller's firm's fund.
Natera Announces Medicare Coverage for Signatera™ Genome
07:00am, Wednesday, 04'th Jun 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medica
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
04:05pm, Monday, 02'nd Jun 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assa
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
05:08pm, Thursday, 22'nd May 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at
Natera: The Clues In Q1 Earnings
08:41am, Friday, 16'th May 2025
Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signater
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
09:30pm, Thursday, 08'th May 2025
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript
08:58pm, Thursday, 08'th May 2025
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
07:00pm, Thursday, 08'th May 2025
Natera (NTRA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.56 per share a year ago.
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
10:30am, Thursday, 08'th May 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
07:00am, Wednesday, 07'th May 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
07:00am, Monday, 05'th May 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study led by Stanford University School of Medici
